Ensign Peak Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$265K Sell
4,515
-700
-13% -$29.4K ﹤0.01% 1232
2026
Q1
$168K Hold
5,215
﹤0.01% 1396
2025
Q4
$220K Sell
5,215
-11,600
-69% -$468K ﹤0.01% 1274
2025
Q3
$577K Sell
16,815
-16,000
-49% -$459K ﹤0.01% 1327
2025
Q2
$887K Hold
32,815
﹤0.01% 1310
2025
Q1
$973K Hold
32,815
﹤0.01% 1263
2024
Q4
$1.3M Hold
32,815
﹤0.01% 1158
2024
Q3
$1.12M Hold
32,815
﹤0.01% 1255
2024
Q2
$711K Hold
32,815
﹤0.01% 1480
2024
Q1
$727K Sell
32,815
-1,655
-5% -$40.4K ﹤0.01% 1509
2023
Q4
$948K Hold
34,470
﹤0.01% 1416
2023
Q3
$770K Hold
34,470
﹤0.01% 1394
2023
Q2
$878K Buy
34,470
+950
+3% +$23K ﹤0.01% 1372
2023
Q1
$747K Buy
33,520
+3,200
+11% +$77.3K ﹤0.01% 1469
2022
Q4
$719K Sell
30,320
-74,528
-71% -$1.73M ﹤0.01% 1432
2022
Q3
$1.74M Buy
104,848
+90,078
+610% +$2.03M ﹤0.01% 833
2022
Q2
$294K Hold
14,770
﹤0.01% 1688
2022
Q1
$407K Hold
14,770
﹤0.01% 1639
2021
Q4
$609K Buy
+14,770
New +$653K ﹤0.01% 1550

Other funds holding VCYT

Ensign Peak Advisors's VCYT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Veracyte (VCYT) stake by 13% in Q2 2026, selling an estimated $29.4K and leaving 4,515 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1232.

Ensign Peak Advisors first reported a position in VCYT in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.74M in Q3 2022. 371 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Ensign Peak Advisors held 4,515 shares of Veracyte worth $265K as of Q2 2026.
  • Ensign Peak Advisors sold 700 Veracyte shares in Q2 2026, an estimated $29.4K.
  • Veracyte made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1232 holding.
  • Ensign Peak Advisors first reported a position in Veracyte in Q4 2021 and has held it in 19 quarters since.
  • Ensign Peak Advisors's Veracyte position peaked at $1.74M in Q3 2022.
  • 371 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.